Skip to content

Contact +44 (0) 20 7060 7474 email us

Medical Devices

Global Cardiovascular Device Markets 2007-2012

 

Publication Date January 2007
Publisher Clinica
Product Type Report
Pages 282
ISBN Number not applicable
Product Code CLI00008

Price

£1,875.00
approximately: $2,839 | €2,093

pdf immediate delivery

Buy Now

Order above formats by FAX

Order by Fax

Summary

Global Cardiovascular Device Markets 2007-2012 is a comprehensive analysis of this important global market and predicts strong growth over the next five years.
This report covers devices for diagnosing and treating cardiac rhythm disorders, coronary artery disease, heart value disorders and end-stage heart failure.

This report will help you:

- Plan your market strategy for the next 5 years
- Identify partnership/investment opportunities
- Analyse the market position of your competitors
- Identify new technologies for licensing
- Assess the competitive landscape for your products
This comprehensive, 250-page report will provide a detailed analysis of:
- Primary segments of the cardiovascular devices market
- Overview of suppliers in the cardiovascular devices market
- Mergers and acquisitions in the cardiovascular devices industry
- Regulatory framework and issues for cardiovascular devices
- Technology developments and trends
- Market application segments
- Trends in individual country markets
- Impact of emerging technologies on competitive structure

Contents

  • Chapter 1 Introduction
    • 1.1 Aims of The report
    • 1.2 Scope of The report
      • 1.2.1 Products included
      • 1.2.2 Markets included
      • 1.2.3 Years covered
      • 1.2.4 Methodology
      • 1.2.5 Forecasting
    • 1.3 Conditions influencing The cardiovascular market
    • 1.4 Lifestyle issues
    • 1.5 Emerging markets
    • 1.6 Regulation and reimbursement issues
    • 1.7 Safety issues
    • 1.8 Emergence of devices vs drugs
    • 1.9 Cardiovascular device manufacturers
    • 1.10 Technology trends
  • Chapter 2 Market overview
    • 2.1.1 Drivers and limiters
  • Chapter 3 Cardiac rhythm management
    • 3.1 Cardiac rhythm background
    • 3.2 Arrhythmias
      • 3.2.1 Types of arrhythmia
        • 3.2.1.1 Bradycardia
        • 3.2.1.2 Tachycardia
        • 3.2.1.3 Ventricular fibrillation
        • 3.2.1.4 Atrial fibrillation
        • 3.2.1.5 Tachyarrhythmias
        • 3.2.1.6 Bradytachycardia
        • 3.2.1.7 Heart block
        • 3.2.1.8 Premature ventricular contractions
    • 3.3 Diagnosis of arrhythmias
    • 3.4 Drug Therapy
    • 3.5 Pacemakers
      • 3.5.1 Single-chamber pacemakers
      • 3.5.2 Dual-chamber pacemakers
      • 3.5.3 Rate responsive pacemakers
      • 3.5.4 Cardiac resynchronisation Therapy pacemaker
      • 3.5.5 Programming
      • 3.5.6 New clinical applications of pacemakers
      • 3.5.7 Companies and products
        • 3.5.7.1 Biotronik
        • 3.5.7.2 Boston Scientific
        • 3.5.7.3 Medtronic
        • 3.5.7.4 Sorin Group
        • 3.5.7.5 St Jude Medical
      • 3.5.8 Factors driving growth
      • 3.5.9 Market data
    • 3.6 Implantable cardioverter defibrillators
      • 3.6.1 Effectiveness and clinical studies
      • 3.6.2 New clinical applications
      • 3.6.3 Companies and products
        • 3.6.3.1 Biotronik
        • 3.6.3.2 Boston Scientific
        • 3.6.3.3 Medtronic
        • 3.6.3.4 Sorin Group
        • 3.6.3.5 St Jude Medical
      • 3.6.4 Factors driving growth
      • 3.6.5 Market data
    • 3.7 Automatic external defibrillators
      • 3.7.1 Effectiveness and clinical studies
      • 3.7.2 Companies and products
        • 3.7.2.1 Cardiac Science
        • 3.7.2.2 GE Healthcare
        • 3.7.2.3 Medtronic
        • 3.7.2.4 Philips Medical
        • 3.7.2.5 Schiller
        • 3.7.2.6 Zoll
      • 3.7.3 Market data
    • 3.8 Pacemaker and defibrillator programmers
      • 3.8.1 Companies and products
        • 3.8.1.1 Biotronik
        • 3.8.1.2 Boston Scientific
        • 3.8.1.3 Medtronic
        • 3.8.1.4 St Jude Medical
        • 3.8.1.5 Sorin
      • 3.8.2 Market dynamics
    • 3.9 Cardiac ablation devices
      • 3.9.1 Companies and products
        • 3.9.1.1 Boston Scientific
        • 3.9.1.2 CryoCath Technologies
        • 3.9.1.3 CryoCor
        • 3.9.1.4 Medtronic
        • 3.9.1.5 St Jude Medical
        • 3.9.1.6 Factors driving growth
      • 3.9.2 Market data
  • Chapter 4 Coronary artery disease
    • 4.1 Myocardial infarction
    • 4.2 Acute myocardial infarction
    • 4.3 Post-myocardial infarction
      • 4.3.1 First line Therapies
        • 4.3.1.1 Beta-blockers
        • 4.3.1.2 ACE Inhibitors
        • 4.3.1.3 Aspirin
        • 4.3.1.4 Thrombolytic Therapy
    • 4.4 Diagnosis
      • 4.4.1 Cardiac markers
      • 4.4.2 Intravascular ultrasound
      • 4.4.3 Magnetic resonance imaging
      • 4.4.4 Computed tomography imaging
      • 4.4.5 CaTheters
    • 4.5 Surgery
      • 4.5.1 Coronary artery bypass graft surgery
      • 4.5.2 Anastomosis devices
      • 4.5.3 Robotic surgery
      • 4.5.4 Beating heart surgery devices
      • 4.5.5 Factors driving growth
      • 4.5.6 Market data
    • 4.6 Angioplasty devices
      • 4.6.1 Factors driving growth
      • 4.6.2 Market
    • 4.7 Stents
      • 4.7.1 Stent types
      • 4.7.2 Stent delivery
      • 4.7.3 Companies and products
      • 4.7.4 Factors driving growth
      • 4.7.5 Market data
    • 4.8 Embolic protection systems
      • 4.8.1 Factors driving growth
      • 4.8.2 Market data
  • Chapter 5 Heart valve disorders
    • 5.1 Introduction
    • 5.2 Valve repair annuloplasty devices
      • 5.2.1 Products
    • 5.3 Mechanical valves
    • 5.4 Tissue valves
      • 5.4.1 Human tissue valves
      • 5.4.2 Animal tissue valves
    • 5.5 PFO devices and devices for closing oTher types of holes in The
      • heart
      • 5.5.1 Patent foramen ovale
      • 5.5.2 Patent ductus arteriosus
      • 5.5.3 Ventricular septal defects
    • 5.6 Factors driving growth
    • 5.7 Market data
  • Chapter 6 End-stage heart failure
    • 6.1 Available Therapies
      • 6.1.1 Angiotensin receptor blockers (ARBs)
      • 6.1.2 Beta-blockers
      • 6.1.3 Digoxin
      • 6.1.4 Diuretics
      • 6.1.5 Aldosterone antagonists
      • 6.1.6 Left ventricular reduction surgery
      • 6.1.7 Intra-aortic balloon pumps
      • 6.1.8 Ventricular reshaping devices
      • 6.1.9 Ventricular assist devices
      • 6.1.10 Artificial hearts
    • 6.2 Companies and products
      • 6.2.1 Abiomed
      • 6.2.2 Arrow International
      • 6.2.3 Berlin Heart
      • 6.2.4 CardiacAssist
      • 6.2.5 MicroMed Technology
      • 6.2.6 Jarvik Heart
      • 6.2.7 MEDOS Medizintechnik AG
      • 6.2.8 SynCardiac Systems
      • 6.2.9 Thoratec
      • 6.2.10 Ventracor
      • 6.2.11 WorldHeart
    • 6.3 Factors driving growth
    • 6.4 Market data
  • Chapter 7 Market analysis by country
    • 7.1 The US
      • 7.1.1 Customer profile
      • 7.1.2 Regulations
      • 7.1.3 Reimbursement
      • 7.1.4 CRM device market
      • 7.1.5 Coronary artery disease device market
      • 7.1.6 Valve disorders market
      • 7.1.7 Congestive heart failure device market
    • 7.2 Japan
      • 7.2.1 Customer profile
      • 7.2.2 Regulations
      • 7.2.3 Reimbursement
        • 7.2.3.1 Type A
        • 7.2.3.2 Type B
        • 7.2.3.3 Type C
        • 7.2.3.4 Type F
      • 7.2.4 CRM device market
      • 7.2.5 Coronary artery disease device market
      • 7.2.6 Valve disorders market
      • 7.2.7 Congestive heart failure device market
    • 7.3 Germany
      • 7.3.1 Customer profile
      • 7.3.2 Regulations
      • 7.3.3 Reimbursement
      • 7.3.4 CRM device market
      • 7.3.5 Coronary artery disease device market
      • 7.3.6 Valve disorders market
      • 7.3.7 Congestive heart failure device market
    • 7.4 France
      • 7.4.1 Customer profile
      • 7.4.2 Regulations
      • 7.4.3 Reimbursement
      • 7.4.4 CRM device market
      • 7.4.5 Coronary artery disease device market
      • 7.4.6 Valve disorders market
      • 7.4.7 Congestive heart failure device market
    • 7.5 The UK
      • 7.5.1 Customer profile
      • 7.5.2 Regulations
      • 7.5.3 Reimbursement
      • 7.5.4 CRM device market
      • 7.5.5 Coronary artery disease device market
      • 7.5.6 Valve disorders market
      • 7.5.7 Congestive heart failure device market
    • 7.6 Italy
      • 7.6.1 Customer profile
      • 7.6.2 Regulations
      • 7.6.3 Reimbursement
      • 7.6.4 CRM device market
      • 7.6.5 Coronary artery disease device market
      • 7.6.6 Valve disorders market
      • 7.6.7 Congestive heart failure device market
    • 7.7 Spain
      • 7.7.1 Customer profile
      • 7.7.2 Regulations
      • 7.7.3 Reimbursement
      • 7.7.4 CRM device market
      • 7.7.5 Coronary artery disease device market
      • 7.7.6 Valve disorders market
      • 7.7.7 Congestive heart failure device market
    • 7.8 China
      • 7.8.1 Customer profile
      • 7.8.2 Regulations
      • 7.8.3 Reimbursement
      • 7.8.4 CRM device market
      • 7.8.5 Coronary artery disease device market
      • 7.8.6 Valve disorders market
      • 7.8.7 Congestive heart failure device market
    • 7.9 India
      • 7.9.1 Customer profile
      • 7.9.2 Regulations
      • 7.9.3 Reimbursement
      • 7.9.4 CRM device market
      • 7.9.5 Coronary artery disease device market
      • 7.9.6 Valve disorders market
      • 7.9.7 Congestive heart failure device market
    • 7.10 The rest of The world
      • 7.10.1 South America
        • 7.10.1.1 Customer profile
        • 7.10.1.2 Argentina
        • 7.10.1.3 Brazil
        • 7.10.1.4 Chile
        • 7.10.1.5 Columbia
        • 7.10.1.6 Mexico
        • 7.10.1.7 Peru
        • 7.10.1.8 Venezuela
      • 7.10.2 South East Asia
        • 7.10.2.1 Customer profile
        • 7.10.2.2 Indonesia
        • 7.10.2.3 Malaysia
        • 7.10.2.4 Philippines
        • 7.10.2.5 Singapore
        • 7.10.2.6 South Korea
        • 7.10.2.7 Taiwan
        • 7.10.2.8 Thailand
        • 7.10.2.9 Vietnam
      • 7.10.3 Australia
        • 7.10.3.1 Customer profile
        • 7.10.3.2 Regulations
        • 7.10.3.3 Reimbursement
        • 7.10.3.4 The market
    • Chapter 8 COMPANY PROFILES
      • 7.10.2.1 Customer profile
        • 7.10.2.2 Indonesia
        • 7.10.2.3 Malaysia
        • 7.10.2.4 Philippines
        • 7.10.2.5 Singapore
        • 7.10.2.6 South Korea
        • 7.10.2.7 Taiwan
        • 7.10.2.8 Thailand
        • 7.10.2.9 Vietnam
        • 7.10.3 Australia
          • 7.10.3.1 Customer profile
          • 7.10.3.2 Regulations
          • 7.10.3.3 Reimbursement
          • 7.10.3.4 The market
      • Chapter 8 Company profiles
      • List of Tables:
        • Table 1.1 Prevalence of hypertension in major medical device markets
      • 2004-2011
        • Table 2.1 US Versus non-US sales of key industry players in 2006
        • Table 2.2 Cardiac rhythm management
        • Table 2.3 Interventional cardiology
        • Table 2.4 Stents
        • Table 2.5 Angioplasty balloons and caTheters
        • Table 2.6 Vascular closure devices
        • Table 3.1 Major suppliers of pacemakers and Their brands
        • Table 3.2 Pacemaker prices in 2005 ($)
        • Table 3.3 European pacing centres per million population
        • Table 3.4 European countries with The highest rates of implanted
        • pacemakers per million population, in 2005
        • Table 3.5 European countries with The lowest rates of implanted
        • pacemakers per million population in 2005
        • Table 3.6 Major suppliers of ICDs and Their brands
        • Table 4.1 MRI and CT installed base per million of population
        • Table 4.2 Trends in average costs by hospital procedure and volume 1988-2000
        • Table 6.1 ACC/AHA Classification of chronic heart failure
        • Table 6.2 New York Heart Association Heart Failure Symptom
        • Classification System
        • Table 6.3 Principal indications for intra-aortic balloon pump
        • Table 6.4 VAD by manufacturer 2007
        • Table 7.1 Cardiovascular operations (thousands) in The US in 2004
        • Table 7.2 Estimated direct costs ($ billion) of cardiovascular disease and Stroke, U.S. 2004
        • Table 7.3 510(k) v PMA approval process in The US
        • Table 7.4 Cardiovascular HRGs in The UK
      • List of Figures:
        • Figure 1.1 Deaths by cause 2005
        • Figure 2.1 Medical device market by sector 2007
        • Figure 2.2 Segmentation of cardiovascular market 2007
        • Figure 2.3 Segmentation of cardiovascular market 2011
        • Figure 3.1 Value of The world pacemaker market ($ millions)
        • Figure 3.2 Company share of The world pacemaker market 2007
        • Figure 3.3 Value of The world ICD market ($ millions)
        • Figure 3.4 Company share of The world ICD market 2007
        • Figure 3.5 Value of The world AED market ($ millions)
        • Figure 3.6 Company share of The world AED market 2007
        • Figure 3.7 Value of The world cardiac ablation market ($ millions)
        • Figure 3.8 Company share of The world cardiac ablation market 2007
        • Figure 4.1 Value of The world cardiac surgical equipment & tools market($ millions)
        • Figure 4.2 Value of The world bypass & disposables market ($ millions)
        • Figure 4.3 Value of The world minimally invasive coronary artery bypass market ($ millions)
        • Figure 4.4 Value of The world angioplasty and balloon caTheter market ($ millions)
        • Figure 4.5 Value of The world bare metal stent market ($ millions)
        • Figure 4.6 Value of The world drug eluting stent market ($ millions)
        • Figure 4.7 Value of The world embolic protection market ($ millions)
        • Figure 5.1 Value of The world tissue heart valve market $ millions
        • Figure 5.2 Company share of The world tissue heart valve market 2007
        • Figure 5.3 Value of The world mechanical heart valve market $ millions
        • Figure 5.4 Company share of The world mechanical heart valve market 2007
        • Figure 5.5 Value of The world heart valve repair market $ millions
        • Figure 5.6 Company share of The world heart valve repair market 2007
        • Figure 6.1 Value of The world VAD market $ millions
        • Figure 6.2 Value of The world intra aortic balloon pump market $millions